e-learning
resources
ERJ
2013
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Reversibility of the monocrotaline pulmonary hypertension rat model
Ruiter Gerrina, de Man Frances S., Schalij Ingrid, Sairras Shellice, Grünberg Katrien, Westerhof Nico, van der Laarse Willem J., Vonk-Noordegraaf Anton
Source:
Eur Respir J 2013; 42: 553-556
Journal Issue:
August
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Ruiter Gerrina, de Man Frances S., Schalij Ingrid, Sairras Shellice, Grünberg Katrien, Westerhof Nico, van der Laarse Willem J., Vonk-Noordegraaf Anton. Reversibility of the monocrotaline pulmonary hypertension rat model. Eur Respir J 2013; 42: 553-556
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Patient with ankylosing spondylitis and pulmonary hypertension
CARDIAC DYSFUNCTION IN ACTIVE PULMONARY TUBERCULOSIS: DOUBLE TROUBLE!!
Related content which might interest you:
Two rat models of hemolysis-induced pulmonary hypertension
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
Bevacizumab administration in monocrotaline induced pulmonary arterial hypertension rat model
Source: Annual Congress 2010 - Pulmonary vascular diseases
Year: 2010
Inflammatory changes in a murine model of monocrotaline-induced pulmonary hypertension
Source: Eur Respir J 2005; 26: Suppl. 49, 365s
Year: 2005
Pirfenidone protects against pulmonary hypertension in the Sugen5416/hypoxia rat model
Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension
Year: 2018
The effect of montelukast on the monocrotaline induced pulmonary disease in the wistar rat
Source: Eur Respir J 2004; 24: Suppl. 48, 561s
Year: 2004
Effect of roflumilast on hypoxia- and monocrotaline-induced pulmonary hypertension in rats
Source: Annual Congress 2007 - Recent advances in the understanding of lung injury and repair
Year: 2007
Bevacizumab administration in pulmonary arterial hypertension rat model decondary to chronical hypoxia exposure
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Effect of zamicastat, a dopamine beta-hydroxylase inhibitor, on the monocrotaline rat model of pulmonary arterial hypertension
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
TRAM-34 ameliorates hypoxia-induced pulmonary arterial hypertension in rats
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
Obesity aggravates monocrotaline–induced pulmonary hypertension in female Zucker rats
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015
Reversal of pulmonary hypertension in a sugen/hypoxic rat model using an ASK1 inhibitor
Source: International Congress 2017 – New perspectives from experimental models of pulmonary hypertension
Year: 2017
The effect of acetazolamide on pulmonary hypertension induced by chronic hypoxia in rats
Source: Annual Congress 2008 - Pulmonary vascular biology
Year: 2008
Regulation of connexins by hypoxia in rat pulmonary vascular cells in an in vitro model of pulmonary hypertension
Source: International Congress 2017 – Experimental PH
Year: 2017
Renal denervation reduces pulmonary vascular remodeling in two experimental pulmonary arterial hypertension models
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015
Effects of BMPR-II signal transduction in the pulmonary vascular remodeling of monocrotaline induced pulmonary hypertension in rats
Source: Annual Congress 2008 - Pathophysiology of pulmonary hypertension
Year: 2008
VIP greatly attenuates monocrotaline-induced pulmonary vasculopathy in rats
Source: Annual Congress 2009 - Pathobiology of pulmonary hypertension
Year: 2009
A novel murine model of severe pulmonary arterial hypertension
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats
Source: Eur Respir J 2011; 37: 813-822
Year: 2011
2-Methoxyestrone inhibits vascular remodeling and attenuates monocrotaline-induced pulmonary hypertension
Source: Annual Congress 2008 - Pulmonary vascular biology
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept